Meeting
2020 Genitourinary Cancers Symposium
Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal cell carcinoma (RCC): A systematic review and meta-analysis.
Authors
Tobias Engel Ayer Botrel
CIOP, Poços de Caldas, Brazil
Tobias Engel Ayer Botrel , Otávio Clark , Francisco Flávio Horta Bretas , Marcus V. Sadi , Ubirajara Ferreira , Luciano Paladini , Wagner Matheus , Ronilson Oliveira Duraes , Antônio Carlos Lima Pompeu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 680)
Abstract #
680
Poster Bd #
F22
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald
Poster
2022 ASCO Annual Meeting
Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.
First Author: Hao Liao
Poster
2022 ASCO Annual Meeting
VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type: Meta-analysis and systematic review.
First Author: Ines Esteves Domingues Pires Da Silva
Poster
2022 ASCO Genitourinary Cancers Symposium
Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.
First Author: Omar Alhalabi